House and Senate sponsors have reintroduced the Cancer Treatment Parity Act, a bill that would require insurers to provide coverage for oral anticancer drugs on terms no less favorable than coverage for intravenous chemotherapy.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
